cases of pulmonary infection, although sensitivity to rifampin and quinolones yielded various results (2–4). Drug susceptibility testing indicated that the isolate we obtained was resistant to ethambutol and rifampin. However, in genetic analyses, mutations associated with ethambutol and rifampin resistance were not detected. According to the Comprehensive Antibiotic Resistance Database, our isolate was resistant to fluoroquinolone, but drug susceptibility test results were inconsistent. Our results indicate that drug susceptibility testing should be performed for M. marseillense to guide antimicrobial drug treatment. If drug susceptibility results are absent, treatments including macrolides and amikacin appear to be reasonable.

Acknowledgments
We thank Jun Chen and Ying Shi for data analysis.

This manuscript was supported by grants from the Chinese Academy of Medical Science Innovation Fund for Medical Science (2017-I2M-B&R-14, 2016-I2M-1-005), Jiangsu Provincial Science and Technology Project (BE2018619), National Science and Technology Major Project (2018ZX10101-001), Graduate Innovation Foundation of Peking Union Medical College (2018-1002-02-13), and Jiangsu Natural Science Foundation (BK20160377).

About the Author
Dr. Xie is a physician in the Department of Dermatology, Zhejiang Institute of Dermatology, Deqing, China, and formerly studied at the Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China. His major research interest is infectious diseases of the skin.

References
1. Ben Salah I, Cayrou C, Raoul D, Drancourt M. Mycobacterium marseillense sp. nov., Mycobacterium timonense sp. nov. and Mycobacterium bouchedourhounense sp. nov., members of the Mycobacterium avium complex. Int J Syst Evol Microbiol. 2009;59:2803–8. https://doi.org/10.1099/ijs.0.010637-0
2. Grottola A, Roversi P, Fabio A, Antenora F, Apice M, Tagliazucchi S, et al. Pulmonary disease caused by Mycobacterium marseillense. Italy. Emerg Infect Dis. 2014;20:1769–70. https://doi.org/10.3201/eid2010.140309
3. Kim SY, Yoo H, Jeong BH, Jeon K, Ha YE, Huh HJ, et al. First case of nontuberculous mycobacterial lung disease caused by Mycobacterium marseillense in a patient with systemic lupus erythematosus. Diagn Microbiol Infect Dis. 2014;79:355–7. https://doi.org/10.1016/j.diagmicrobio.2014.03.019
4. Azzali A, Montagnani C, Simonetti MT, Spinelli G, de Martinio M, Galli L. First case of Mycobacterium marseillense lymphadenitis in a child. Ital J Pediatr. 2017;43:92. https://doi.org/10.1186/s13052-017-0413-5
5. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al.; American Thoracic Society Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. (Erratum in: Am J Respir Crit Care Med 2007;175:744–5.) Am J Respir Crit Care Med. 2007;175:367–416. https://doi.org/10.1164/rcrm.200604-571ST
6. Abdallah AM, Gey van Pittius NC, DiGiuseppe Champion PA, Cox J, Luirink J, Vandenbroucke-Grauls CMJE, et al. Type VII secretion—mycobacteria show the way. Nat Rev Microbiol. 2007;5:883–91. https://doi.org/10.1038/nrmicro1773
7. Chen Y, Jiang J, Jiang H, Chen J, Wang X, Liu W, et al. Mycobacterium gordona in patient with facial ulcers, nosebleeds, and positive T-SPOT.TB test. China. Emerg Infect Dis. 2017;23:1204–6. https://doi.org/10.3201/eid2307.162033

Address for correspondence: Hongsheng Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Institute of Dermatology, St 12 Jiangwangmiao, Nanjing, Jiangsu, 210042, China; email: whs33@vip.sina.com

Geospatial Variation in Rotavirus Vaccination in Infants, United States, 2010–2017

Mary A.M. Rogers, Catherine Kim, Annika M. Hofstetter

Author affiliations: University of Michigan, Ann Arbor, Michigan, USA (M.A.M. Rogers, C. Kim); University of Washington and Seattle Children’s Research Institute, Seattle, Washington, USA (A.M. Hofstetter)

DOI: https://doi.org/10.3201/eid2510.190874

We evaluated rotavirus vaccination rates in the United States by using records from a nationwide health database. From data on 519,697 infants, we found 68.6% received the entire rotavirus vaccine series. We noted pockets of under-vaccination in many states, particularly in the Northeast and in some western states.

Vaccination coverage in the United States frequently is evaluated by telephone and mailed surveys (1). However, telephone response rates have declined over the past 2 decades (2) and parents who choose not to vaccinate their children might be less likely to participate in surveys (3).
The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination among US infants to prevent rotavirus infection, the most common cause of gastroenteritis in children worldwide (4). We designed a study to evaluate rotavirus vaccination rates using nationwide health insurance records.

We conducted a longitudinal study of rotavirus vaccination rates during January 1, 2010–June 30, 2017. We obtained deidentified data from Clinformatics Data Mart (Optum, https://www.optum.com), an integrated database containing demographic, service type (inpatient and outpatient), medication, and laboratory data for ≈77.8 million privately insured persons of all ages across 50 states. We included data on infants (<1 year of age) with continuous health insurance enrollment from birth to 1 year of age and an available residential ZIP code. We determined completion of the rotavirus vaccine series by using Current Procedural Terminology (CPT) codes and data on vaccine administration, including vaccine type, date, and location. Vaccine completion requires 2 doses of monovalent Rotarix (GlaxoSmithKline, https://www.gsk.com; CPT 90681) or 3 doses of pentavalent RotaTeq (Merck and Company, https://www.merck.com; CPT 90680). To evaluate geographic variation, we used the first 3 digits of residential ZIP codes and excluded areas with <20 infants to provide stability of the estimates. The study was reviewed and deemed exempt by the institutional review board of the University of Michigan.

We identified 526,376 infants with continuous health insurance for ≥1 year during 2010–2017. We excluded 5,708 (1.1%) with no known residential ZIP code and 971 (0.2%) from areas with <20 infants. Our final cohort contained 519,697 eligible infants; 99.8% had no copayment for vaccine administrations. The number of infants in each 3-digit ZIP code area was 20–9,426 (median 223; interquartile range 85–682).

In our cohort, 68.6% (95% CI 68.5%–68.8%) of infants completed the rotavirus vaccine series; 15.9% completed only part of the series, and 15.5% received no rotavirus vaccine. Of infants completing the vaccine series, 79% received RotaTeq, 19% received Rotarix, and 2% received both. The mean interval between vaccine doses was 64.9 days.

Rotavirus vaccination rates were higher in eastern states, although some states in the Northeast had low proportions of vaccination (Figure). Alaska had considerably lower vaccination rates, ranging from 17% to 28%. Series completion was lowest in northeastern Wyoming at 9%.

Figure. Percentage of infants (<1 year of age) covered by private health insurance who completed the rotavirus vaccination series in the United States, 2010–2017.
(95% CI 4%–17%) and highest (>80%) in upstate New York, several areas of Pennsylvania, and 1 suburb of San Francisco, California.

Rotavirus vaccination coverage varied considerably across the United States, with pockets of undervaccination in many states. National Immunization Survey (NIS) data show ≈59.2% of infants completed the rotavirus vaccine series in 2010 and ≈73.2% completed the series in 2017 (1,5). Our overall estimate was 68.6% during 2010–2017 among privately insured infants. However, we note several differences in these samples. NIS used a nationwide sample of 15,333 children in 2017, whereas our study used 34× that number (519,697), giving us an opportunity to assess vaccination rates in local areas. NIS weights for nonparticipation but could underestimate coverage rates in less densely populated areas (6). Our use of deidentified data rather than telephone surveys might provide an opportunity to include vaccine-hesitant populations (3). However, our sample does not shed light on vaccination rates in children covered under Medicaid or the Children’s Health Insurance Program or those with no insurance coverage.

Parents’ decision to vaccinate their children involves a complex interplay between advice from family and friends; school and institutional mandates; experience with healthcare professionals; personal beliefs; and social impacts, including media coverage, access, and transportation issues (7). The geographic variation in vaccination rates we found might reflect some of these determinants. For instance, low coverage in remote areas may reflect an inability to travel to providers; lower overall vaccination rates have been found in children living in rural areas (1,8). Because 99.8% of our cohort did not have a copayment, we do not believe there was financial disincentive, but other financial obstacles could exist. Previous studies suggest rotavirus vaccination is lower among persons with public or no insurance (9). Therefore, vaccination rates might be <68% in geographic regions with a high number of uninsured or underinsured children.

The 15.9% of infants in our cohort who did not complete the vaccine series could reflect an inability to meet the start- and end-date requirements. Rotavirus vaccination has an exceptionally narrow window of administration; ACIP recommends the first dose at <15 weeks of age and conclusion of all doses before 8 months of age.

In summary, we found considerable geographic variation in rotavirus vaccination rates in the United States. We recommend additional efforts at the local and county levels to address pockets of rotavirus undervaccination.

Acknowledgments
This study was funded by the National Institutes of Health (grant no. UL1TR000433) and was carried out in accordance with National Institutes of Health guidelines for studies that utilize deidentified data from humans.

About the Author
Dr. Rogers is an epidemiologist and research associate professor at the University of Michigan, Ann Arbor, Michigan, USA. Her research interests include preventive medicine and translational research.

References
1. Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kang Y. Vaccination coverage among children aged 19–35 months—United States, 2017. MMWR Mortal Wkly Rep. 2018; 67:1123–8. https://doi.org/10.15585/mmwr.mm6740a4
2. Nishimura R, Wagner J, Elliott MR. Alternative indicators for the risk of non-response bias: a simulation study. Int Stat Rev. 2016;84:43–62. https://doi.org/10.1111/insr.12100
3. Salmon DA, Moulton LH, Omer SB, DeHart MP, Stolley S, Halsey NA. Factors associated with refusal of childhood vaccines among parents of school-aged children: a case–control study. Arch Pediatr Adolesc Med. 2005;159:470–6. https://doi.org/10.1001/archpedi.159.5.470
4. Centers for Disease Control and Prevention. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2009;58(RR02):1–25.
5. Centers for Disease Control and Prevention. National and state vaccination coverage among children aged 19–35 months—United States, 2010. MMWR Morb Mortal Wkly Rep. 2011; 60:1157–63.
6. Groves RM, Peytcheva E. The impact of nonresponse rates on nonresponse bias: a meta-analysis. Public Opin Q. 2008; 72:167–89. https://doi.org/10.1093/poq/nfn011
7. Sturm LA, Mays RM, Zimet GD. Parental beliefs and decision making about child and adolescent immunization: from polio to sexually transmitted infections. J Dev Behav Pediatr. 2005;26:441–52. https://doi.org/10.1097/00004703-200501200-00009
8. O’Leary ST, Barnard J, Lockhart S, Kolasa M, Shmueli D, Dickinson LM, et al. Urban and rural differences in parental attitudes about influenza vaccination and vaccine delivery models. J Rural Health. 2015;31:421–30. https://doi.org/10.1111/jrh.12119
9. Aliabadi N, Wikswo ME, Tate JE, Cortese MM, Szilagyi PG, Staat MA, et al. Factors associated with rotavirus vaccine coverage. Pediatrics. 2019;143:e20191542. https://doi.org/10.1542/peds.2018-1824

Address for correspondence: Mary A.M. Rogers, University of Michigan, Bldg 16, Rm 422W, North Campus Research Complex, 2800 Plymouth Rd, Ann Arbor, MI 48109–2800, USA; email: maryroge@umich.edu